Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

70 5 Major Histocompatibility Complex Modulation and Loss
A
B
Fig. 5.10 Association of defects in components
of the APM with HLA class I antigen down-regulation.
The deficient MHC class I surface expres-
sion can be caused by (A) dysregulation of different
APM components or (B) structural defects
in APM components, in particular of TAP.
Tab. 5.2 Loss or down-regulation of MHC class I antigens due to deficiencies in the MHC class I
APM
Tumor cell line Tumor type Molecular alterations References
Buf1280 melanoma bp deletion in TAP1 162.,
in preparation
H1436 small cell lung carcinoma CGG ? CAG in exon 10 of TAP1 148
FM55, FM37, melanoma regulatory defect 149, 150, 151, 161
NW16, 453A,
136-2, 823,
634, 603
PCC-1 prostate regulatory defect 151
H1092, H82 small cell lung carcinoma regulatory defect 152
MZ1257RC, RCC regulatory defect 160
MZ1851RC,
MZ1940RC
HS C5, HSC 7 HNSCC regulatory defect 60
tinct histology (Tab. 5.2). There exists a heterogeneity in terms of quantity and quality
of stained cells. In comparison to normal corresponding cells, LMP2 and LMP7
expression is reduced in Burkitt lymphoma lesions, in some breast carcinomas and
in melanoma as well as in RCC, although the LMP subunits appear not always to
be coordinately down-regulated in these tumor specimens [54]. Similar to the surgi-